Next Genetic Natural Stem Cell Therapy Established : Nationaly Registered T-Protocol Of Genom Project Successfully Applied To Retrieve Bio Mechanism Of Hair Regrowth
Released on: January 13, 2011, 7:02 am
Author:
Science Gene Medicine
Industry:
Biotech,
Healthcare
Division of Gene Medicine & Stem Cell Application, School of
Medical Science, complete the research and established completely new
protocol totally recovering natural bio mechanism of hair regrowth.
The researchers, led by Lord. Prof. Dr. Daichent Otto Rie, specified protein and genom
to affect internal bio mechanism to generate hair and control the level of
successful growth being low which is the baldness.
The key cast of the set of the bio cycle is hair follicles, which is stem cell on
head skin and effect or holding function to cure many neurotic diseases and
disorders like Alzheimer's disease - Prion Disease and even Trion
Disease (Post Hetero-Plastic Implantation Chronic Inflammation Syndrome; PhCIS) has
absolutely unique character being retrieved absolute stem cell, which can recover the
ability as stem cell after got adult. The key genom and DNA has been found through
the Genom Project's T-Protocol research developing in the government registered
Genom Project since 2005. The most concentrated attention of researchers is not "what is cause" but "What protocol is best".
The team of Prof.Daichent has successfully completed in vivo and in vivro
experiment actually using voluntary patients whose types of hair loss being across
over highly wide range extent to even lymphoma and cancer and finally established
next genetic hair loss curing treatment protocol mainly composed of stem cell
therapy and gene therapy.
Most of cases are treatable through entry level stem cell theraputic technique or
HIV-1 Vector using high level technique but A20 introduction as gene therapy is
required when treating patients being suffered from lymphoma, cancer or any neurotic
diseases like Alzheimer's disease - Prion Disease and even Trion Disease (Post
Hetero-Plastic Implantation Chronic Inflammation Syndrome; PhCIS).
As Prof.Daichent points since 2005 being on School of Public Health of Harvard, in
the treatment manual (published 2005), the key factor to overcome of lymphoma and
chronic inflammation on human skin is extraordinary redundancy coding of
polyglutamine DNA synthesis as the type of disease caused by pathological proteins
and lack or heavy impairment of an specific DNA of A20.
Actually, the treatment protocol curing for baldness is also found through
T-protocol which was essentially aimed at achieving causal and complete treatment of
lymphoma, cancer, chronic inflammation and many neurotic diseases. Under control
over the T-Protocol, all of clinical practitioner must always keep their eyes on the
fact of using steroid is taboo over administration so being strictly prohibited. And
also the technique must be under control of the competent faculty accredited by board
in accordance with Europ.Gene Institute or specifically set physically area solely
for research and clinical practice of nations like Switzerland, Germany, India,
Hongkong, U.K. territories (NEVER inside U.K.) appointed by protocol developer and
assigned practice entity.
Absolutely the set of treatment using gene therapy of A20 injection is totally
successful and contributes high degree of extension of patients' life. As ordinary
treating way in general and internal medicine, an new drug to treat chronic
inflammation, lymphoma and neurotic diseases including Trion Disease has been made
up and already delegated the scheme and title to produce forward a Euro.Pharma.co.
under preparation distributing for chronic inflammation and lymphoma.
An patient who hopes the treatment by T-Protocol (occasionally consulting
Prof.Daichent) could be cared by referral basis.
Contact Details: General Matter: genemed.science@vistomail.com
Genom Project Matter: http://www.ncbi.nlm.nih.gov
T-Protocol Treatment Matter: medinfo@vistomail.com
or near RMP accredited issuing referral
Back to previous page
Home page
Submit your press release
2025
